ONCC Practice Tests (OCN - Symptom
Management and Palliative Care) – Q and
A
Which of the following is a dose-limiting toxicity of irinotecan?
Diarrhea
Miosis
Vomiting
Alopecia - -Diarrhea
Answer: Diarrhea is the dose-limiting toxicity for irinotecan.
Reference: Polovich, M., Olsen, M., & LeFebvre, K. (Eds.). (2014).
Chemotherapy and biotherapy guidelines and recommendations for practice
(4th ed.). Pittsburgh, PA: Oncology Nursing Society, p. 44(t).
-Administration of filgrastim maintains the dose intensity of a treatment
regimen by reducing the:
occurrence of febrile neutropenia.
need for leucovorin rescue.
occurrence of nausea and vomiting.
risk of cardiotoxicity. - -occurrence of febrile neutropenia.
Answer: Filgrastim is used to reduce the risk of febrile neutropenia.
Reference: Eggert, J. (Ed.). (2017). Cancer basics (2nd ed.). Pittsburgh, PA:
Oncology Nursing Society, pp. 227-228.
-One year after receiving total body irradiation for a hematopoietic stem cell
transplant, a patient reports increasingly dim vision and ocular sensitivity.
The nurse suspects which late effect related to treatment?
Cataracts
Macular degeneration
Strabismus
Optic nerve dysfunction - -Cataracts
Answer: Patients who receive total body irradiation are at greater risk for the
development of cataracts.
, Reference: Yarbro, C.H., Wujcik, D., & Gobel, B.H. (Eds.). (2018). Cancer
nursing: Principles and practice (8th ed.). Burlington, MA: Jones and Bartlett,
p. 602.
-A 78-year-old patient with prostate cancer and cardiovascular disease is
taking naproxen twice a day and a daily dose of acetylsalicylic acid. The
nurse instructs the patient to:
speak with the physician about adding a cytoprotectant.
space the medications at least one hour apart.
take the medications on an empty stomach.
expect an increase in swelling of the extremities during the evening. - -
speak with the physician about adding a cytoprotectant.
Answer: Patients receiving cyclooxygenase-1 inhibitors who are high risk
based on existing cardiac disease should consider the addition of a
cytoprotectant.
Reference: Yarbro, C.H., Wujcik, D., & Gobel, B.H. (Eds.). (2018). Cancer
nursing: Principles and practice (8th ed.). Burlington, MA: Jones and Bartlett,
p. 801(t).
-A patient receiving a fluorouracil-based combination chemotherapy
regimen is employed as a landscaper. The nurse teaches the patient about
the risk of:
photosensitivity.
pulmonary toxicity.
peripheral edema.
gout. - -photosensitivity.
Answer: Photosensitivity is a side effect of fluorouracil.
Reference: Polovich, M., Olsen, M., & LeFebvre, K. (Eds.). (2014).
Chemotherapy and biotherapy guidelines and recommendations for practice
(4th ed.). Pittsburgh, PA: Oncology Nursing Society, p. 34(t).
-A patient who reports nausea four days after receiving chemotherapy is
experiencing which type of chemotherapy-induced nausea?
Delayed
Acute
Refractory
Breakthrough - -Delayed
Management and Palliative Care) – Q and
A
Which of the following is a dose-limiting toxicity of irinotecan?
Diarrhea
Miosis
Vomiting
Alopecia - -Diarrhea
Answer: Diarrhea is the dose-limiting toxicity for irinotecan.
Reference: Polovich, M., Olsen, M., & LeFebvre, K. (Eds.). (2014).
Chemotherapy and biotherapy guidelines and recommendations for practice
(4th ed.). Pittsburgh, PA: Oncology Nursing Society, p. 44(t).
-Administration of filgrastim maintains the dose intensity of a treatment
regimen by reducing the:
occurrence of febrile neutropenia.
need for leucovorin rescue.
occurrence of nausea and vomiting.
risk of cardiotoxicity. - -occurrence of febrile neutropenia.
Answer: Filgrastim is used to reduce the risk of febrile neutropenia.
Reference: Eggert, J. (Ed.). (2017). Cancer basics (2nd ed.). Pittsburgh, PA:
Oncology Nursing Society, pp. 227-228.
-One year after receiving total body irradiation for a hematopoietic stem cell
transplant, a patient reports increasingly dim vision and ocular sensitivity.
The nurse suspects which late effect related to treatment?
Cataracts
Macular degeneration
Strabismus
Optic nerve dysfunction - -Cataracts
Answer: Patients who receive total body irradiation are at greater risk for the
development of cataracts.
, Reference: Yarbro, C.H., Wujcik, D., & Gobel, B.H. (Eds.). (2018). Cancer
nursing: Principles and practice (8th ed.). Burlington, MA: Jones and Bartlett,
p. 602.
-A 78-year-old patient with prostate cancer and cardiovascular disease is
taking naproxen twice a day and a daily dose of acetylsalicylic acid. The
nurse instructs the patient to:
speak with the physician about adding a cytoprotectant.
space the medications at least one hour apart.
take the medications on an empty stomach.
expect an increase in swelling of the extremities during the evening. - -
speak with the physician about adding a cytoprotectant.
Answer: Patients receiving cyclooxygenase-1 inhibitors who are high risk
based on existing cardiac disease should consider the addition of a
cytoprotectant.
Reference: Yarbro, C.H., Wujcik, D., & Gobel, B.H. (Eds.). (2018). Cancer
nursing: Principles and practice (8th ed.). Burlington, MA: Jones and Bartlett,
p. 801(t).
-A patient receiving a fluorouracil-based combination chemotherapy
regimen is employed as a landscaper. The nurse teaches the patient about
the risk of:
photosensitivity.
pulmonary toxicity.
peripheral edema.
gout. - -photosensitivity.
Answer: Photosensitivity is a side effect of fluorouracil.
Reference: Polovich, M., Olsen, M., & LeFebvre, K. (Eds.). (2014).
Chemotherapy and biotherapy guidelines and recommendations for practice
(4th ed.). Pittsburgh, PA: Oncology Nursing Society, p. 34(t).
-A patient who reports nausea four days after receiving chemotherapy is
experiencing which type of chemotherapy-induced nausea?
Delayed
Acute
Refractory
Breakthrough - -Delayed
